Vertex Pharmaceuticals (VRTX) Payables (2009 - 2026)

Vertex Pharmaceuticals has reported Payables for 18 years, with the latest figure at $489.3 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 9.96% year-over-year to $489.3 million; the trailing twelve-month figure through Mar 2026 stood at $489.3 million (up 9.96% YoY), and the FY2025 full-year result was $461.7 million, up 11.79% from the prior year.
• Payables for Q1 2026 stood at $489.3 million, up from $461.7 million in the prior quarter.
• The five-year high for Payables was $489.3 million in Q1 2026, with the low at $126.9 million in Q3 2022.
• Average Payables over 5 years is $351.5 million, with a median of $364.9 million recorded in 2023.
• Year-over-year, Payables jumped 196.22% in 2023 and dropped 9.67% in 2024.
• Tracing VRTX's Payables over 5 years: stood at $303.9 million in 2022, then advanced by 20.07% to $364.9 million in 2023, then climbed by 13.18% to $413.0 million in 2024, then rose by 11.79% to $461.7 million in 2025, then grew by 5.98% to $489.3 million in 2026.
• The last three Payables figures came in at $489.3 million (Q1 2026), $461.7 million (Q4 2025), and $420.3 million (Q3 2025), per Business Quant data.

Peer Comparison